ArticleMultiple sclerosis journal - experimental, translational and clinical

Health-economic benefits of anti-CD20 treatments in relapsing multiple sclerosis estimated using a treatment-sequence model.

Ide Smets et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.